CalciMedica (CALC) 10% owner reports 5.1M shares plus AKI trial-linked warrants

Rhea-AI Filing Summary

ALAFI CAPITAL CO LLC, a greater-than-10% owner of CalciMedica, Inc., reported beneficial ownership of 5,112,345 shares of Common Stock. It also holds Common Share Warrants exercisable for 130,651 shares of Common Stock at an exercise price of $7.15 per share. The warrants were issued on July 22, 2025 and expire on the earlier of 5:00 p.m. New York City time on December 31, 2026 or 30 days following the company’s public disclosure of topline results from its planned Phase 2 clinical trial in patients with acute kidney injury.

Insights

Securities law analyst

Initial Form 3 showing a large ownership stake and warrant position.

ALAFI CAPITAL CO LLC is identified as a more-than-10% beneficial owner of CalciMedica, Inc. with 5,112,345 Common Stock shares and warrants for 130,651 additional shares at an exercise price of $7.15.

The warrants were issued on July 22, 2025 and will expire on the earlier of December 31, 2026 or 30 days after public disclosure of topline results from a planned Phase 2 clinical trial in acute kidney injury. This timing links warrant value to the outcome and disclosure of that trial.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider ALAFI CAPITAL CO LLC

Role 10% Owner

Type	Security	Shares	Price	Value
holding	Common Share Warrants F1, F2	--	--	--
holding	Common Stock	--	--	--

Holdings After Transaction: Common Share Warrants — 130,651 shares (Direct); Common Stock — 5,112,345 shares (Direct)

Footnotes (2)

1. F1. The issue date of the warrants is July 22, 2025.
2. F2. The expiration of these Warrants is the earlier of (i) 5:00pm (New York City time) on December 31, 2026 and (ii) 30 days following the Company's public disclosure of topline results from the Company's planned Phase 2 clinical trial in patients with acute kidney injury.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Understanding Insider Trading Forms →

Available on EDGAR 07/10/2026 - 05:36 PM Accepted by SEC EDGAR 07/10/2026 - 05:36 PM Learn about SEC filing dates

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

ALAFI CAPITAL CO LLC

(Last) (First) (Middle)

8 ADMIRAL DRIVE, SUITE 324

(Street)

EMERYVILLE CALIFORNIA 94608

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
06/25/2026

3. Issuer Name and Ticker or Trading Symbol
CalciMedica, Inc. [ CALC ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	5,112,345	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Common Share Warrants	(1)	(2)	Common Stock	130,651	$7.15	D

Explanation of Responses:

1. The issue date of the warrants is July 22, 2025.

2. The expiration of these Warrants is the earlier of (i) 5:00pm (New York City time) on December 31, 2026 and (ii) 30 days following the Company's public disclosure of topline results from the Company's planned Phase 2 clinical trial in patients with acute kidney injury.

	Christopher D. Alafi, as managing member of Alafi Capital Company, LLC	07/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)